Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
Stockholm, Sweden, April 24, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the first quarter 2024, in conjunction with their partner Biogen’s first quarter report. In total, sales of JPY 2.83 billion were recorded in the period, resulting in a royalty to BioArctic amounting to approximately SEK 18 million.Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making